- Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a 3-week (Pfizer) or 4-week (Moderna) interval for people who are immunocompromised, over 65 years old or need rapid protection because of risk of transmission or severe outcomes. Providers decide which interval is best for patients based on benefits and risk factors.
- See CDC Clinician Outreach and Communication Activity (COCA) call slides for more information.
- Be aware, on Feb. 24, Food and Drug Administration (FDA) revised its Evusheld emergency use authorization (EUA) (tixagevimab co-packaged with cilgavimab). When used for COVID-19 pre-exposure prophylaxis, the new initial dose is 300 mg tixagevimab and 300 mg cilgavimab. Recent data shows Evusheld may be less active against some Omicron subvariants. Contact patients who received the previous initial dose (150 mg tixagevimab and 150 mg cilgavimab) and ask them to return for an additional 150 mg tixagevimab and 150 mg cilgavimab.
- See updated Evusheld EUA for more information.
- Be aware, CDC updated its list of underlying medical conditions associated with higher risk of severe outcomes from COVID-19 to include primary immunodeficiency and physical inactivity. The list is not exhaustive. Do not use it to exclude people from recommended preventive measures, like booster doses or needed therapies.
- See National Institutes of Health (NIH) COVID-19 treatment guidelines for more information.
- Strongly recommend patients get COVID-19 vaccine. You are patients’ most trusted source of vaccine information.
- Teach patients how to access, use and interpret at-home antigen test kits. Direct patients to the many testing locations in the area.
In people 18–39 years old, myocarditis occurs in an estimated 23–33 per million people following a second dose of mRNA COVID-19 vaccine. Nearly all cases are transient and can be treated on an outpatient basis. Recent research shows increasing the interval between first and second doses of mRNA COVID-19 vaccine from 3–4 weeks to 8 weeks can reduce the risk of myocarditis by over half while also substantially improving efficacy.
CDC guidance allows clinicians to decide when the benefits of the extended interval exceed the increased risk of COVID‑19 infection. Regardless of the interval between first and second doses, a booster dose should be delivered no sooner than 5 months after the second dose. These changes do not affect people with compromised immune systems or people over 65 years old, as the risk of COVID-19 infection outweighs the benefit of reduced myocarditis incidence.
Additional COVID-19 vaccine information
- Clinical considerations for the use of COVID-19 vaccine, CDC.
- COCA call slides, CDC.
- Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada, Buchan, et. al.
- Booster dose updates, FDA.
- EUA and FDA-approved vaccine information:
- COVID-19 vaccine locator, Washington State Department of Health (DOH).
- COVID-19 vaccine provider toolkit and resources, DOH.
- COVID-19 vaccination for providers, CDC.
- Clinical considerations for COVID-19 vaccination and guidance for managing anaphylaxis, CDC.
- COVID-19 vaccine quick reference guide for healthcare professionals, CDC.
- COVID-19 vaccine training module on best practices for providers, CDC.
COVID-19 test processing
Labs report varying amounts of time to process COVID-19 tests. To support faster turnaround, we encourage providers to use in-state labs. The table below shows COVID-19 test processing times for in-state private labs. If you have questions about Health Department-facilitated antigen tests, contact firstname.lastname@example.org.
|Lab||Time to process test||Tests processed daily|
|Northwest Pathology||24 hours||3,000|
|UW Virology||12–24 hours||10,000–11,000|
|Atlas Genomic||24–48 hours||10,000|
Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapies. Email email@example.com for support enrolling.
Once enrolled, to request a supply of monoclonal antibodies or therapeutics, complete a smart sheet.
Supplies of all therapies are currently limited. Commercial and independent pharmacies may have oral antivirals. Hospital-associated systems may have monoclonal antibodies. All therapies must be dispensed by prescription. Therapies from pharmacies may be intended for home delivery. Patients with questions about accessing their medication should call the pharmacy.
- HHS COVID-19 therapeutics locator for providers.
- DOH therapeutics for providers page.
- NIH COVID-19 treatment guidelines.
Share with patients:
- What to do if you test positive for COVID-19.
- What to do if you were exposed to someone with COVID-19.
Immediately report COVID-19Fax the positive lab results or a completed Reportable Disease Fax Form to our confidential fax (360) 813-1168. If needed, call Kitsap Public Health by calling (360) 728-2235.
Contacting the Health DepartmentQuestions? Contact Kitsap Public Health District at (360) 728-2235.
- CDC COVID-19 Health Equity Resources.
- Our COVID-19 page for healthcare providers.
- Washington COVID-19 risk assessment dashboard.
- CDC guidance for healthcare providers and facilities.
- DOH COVID-19 data dashboard.
- DOH COVID-19 page.
- CDC COVID-19 page.
- Pierce County COVID-19 response and recovery page.
- Pierce County personal protective equipment (PPE) requests.
- SARS-CoV-2 sequencing and variants in Washington.